Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seems to me that earnings was better than expected... Should run the next days from here.
Bullish butterfly pattern
From Marcos7 as promised my trading Amigos! This is the potential bullish butterfly pattern. A lot of moves. First a quick move up towards $15.70 with the lowest at $6.90 before the move. And then a drop to the right wing and a massive flight to $34.42 a total of 335% from today’s price. See you in the bounce!??????????
Added a few more now I’m out of funds. So please no more dips...
We will be happy later on. :)
Me tooo... SOO good to be back $FSR
Added more shares today. This is sickness go $SRNE..
Can´t wait till we get more news!!! $PDSB is a GEM.. Diamond Hands.
I am back in :) go $FSR
Sold @ $26 now tomorrow I will go back in for long term investment.
$SRNE Sorrento sues the former CEO of its one-time Chester County subsidiary Scilex
From Bizjournals another company messing with Sorrento products.
https://www.bizjournals.com/philadelphia/news/2021/03/16/scilex-sorrento-virpax-lawsuit-malvern-pain-drugs.html
By John George – Senior Reporter, Philadelphia Business Journal Mar 16, 2021
A California biotechnology company has filed a lawsuit against the former CEO of a Chester County life sciences company it acquired more than four years ago.
Sorrento Therapeutics (NASDAQ: SRNE) of San Diego and the company it acquired, Scilex Pharmaceuticals, filed a lawsuit last week in the Delaware Court of Chancery against Virpax Pharmaceuticals CEO Anthony Mack and Virpax itself.
The lawsuit alleges Mack breached the "restrictive covenants agreement" he entered into with Sorrento when he sold all of his shares in Scilex to Sorrento for about $12 million on Nov. 8, 2016. The lawsuit also alleges Virpax interfered with that agreement. Sorrento and Scilex are seeking unspecified financial damages and an injunction to enforce the covenants.
When asked about the lawsuit, Mack said, "We do not believe the claims have merit; our lawyers will be presenting our position in court.”
Sorrento said it learned of Virpax through documents it filed with the Securities and Exchange Commission after the company completed a small initial public stock offering last month, raising $18 million through the sale of 1.8 million shares of its common stock at $10 per share.
Sorrento acquired Scilex — which at the time was based in Malvern — in a deal valued at $47.6 million in 2016. Scilex, which continues to operate as a California-based subsidiary of Sorrento, received Food and Drug Administration approval for its non-opioid pain medicine ZTlido in 2018.
Following the sale, the lawsuit states, Mack agreed to stay on as president of Scilex and was paid an annual salary of more than $300,000.
As part of the deal, according to the lawsuit, Mack committed to not entering a relationship with any other company that would compete directly or indirectly with Scilex’s flagship pain-management product ZTlido or any business related to that product for a period of two years after he sold his Scilex stock to Sorrento.
Mack resigned as president of Scilex in March of 2018. He founded Virpax in early 2017. It is not clear when Virpax became operational. The company's product candidates include a “patch-in-a-can," aerosol-based pain treatment that is sprayed onto the skin.
The lawsuit states Mack allegedly violated the agreement with Sorrento by forming and operating Virpax, a competing company that allegedly acquired technologies and is developing products directly competitive with ZTlido and Scilex’s related business. Sorrento, in its lawsuit, alleges Mack "worked diligently and in secret to use various Scilex relationships and third-party technologies in Scilex’s pipeline to benefit Virpax."
In the lawsuit, Sorrento and Scilex management stated after learning of the Virpax initial public offering of stock they "further analyzed Mack’s conduct and Virpax’s business, including a review of Mack’s email activity while he worked at Scilex and other available information about Virpax’s business" to determine the alleged breaches of the restrictive covenants.
The lawsuit alleges Virpax is developing three pain management products that are directly derived from technologies that were in Scilex’s pipeline and, if authorized by the FDA, would compete with ZTlido.
$SRNE
Hold your shares, don't put any sell off limits BUT every day make a set up sales at 50$....Therefore no more opportunity for letting hedges to borrow our shares anymore!!!!! If the stock is set up for sales they cannot take it!!! They are killing us with our shares!!! Set up sales at 50$ every day!!!
Huge huge....
http://attachment.aconnect.com.hk/Attachment/64471
I can feel a PR is on the way!!
Amazon Receives FDA approval for Covid Test kits.
https://www.reddit.com/r/srne/comments/me2u0x/amazon_receives_fda_approval_for_covid_test_kits/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
From Reddit $SRNE community:
Sorrento positive results from MSC. SRNE the Tesla of biotech companies
Considering today's release you may want to familiarize yourself with COVI-MSC & PSC's Robert J. Harman. Below is a revealing white paper detailing the efficacy & safety vs. vaccines. Sorrento's Oct 14th agreement with PSC (Personalized Stem Cells) might be a winner.. looks to be the treatment catalyst we may see first.
"Human clinical trials of MSC therapy in COVID-19
Despite the fact that COVID-19 was first reported only recently, several clinical studies on MSC therapy have been published. Liu and colleagues retrospectively analyzed the differences between 109 COVID-19 patients with and without ARDS. Patients had a mean of age 55 years old with a median follow-up of 15 days. The overall survival rate was 71.6%. Of all the patients, 48.6% developed ARDS. Compared to non-ARDS patients, ARDS patients were older and more likely to have coexistent morbidities. No significant effect on survival was observed in these patients despite the use of antivirus, glucocorticoid, or immunoglobulin treatments [239].
Liang and colleagues [240] reported the treatment of a critically ill 65-year-old female infected with SARS-CoV-2. On January 27, 2020 the patient presented with fatigue, fever and cough. The following day she developed chest tightness, hypoxia and hypertension and tested positive for 2019 novel coronavirus. Radiographs revealed ground glass opacity and 2 days later she was admitted to the hospital. She was initially treated with antiviral therapy (lopinavir/ritonavir), IFN-? inhalation, oseltamivir, and IV injection of moxifloxacin, Xuebijing, methylprednisolone and immunoglobulin. Her breathing was maintained with a non-invasive mechanical ventilator. Days later she was diagnosed with critically ill type COVID-19 with acute respiratory failure and was transferred to the ICU for ventilator support. Eventually, the glucocorticoid and antiviral therapies were withdrawn, and 1 week later, 50?×?106 allogeneic UC-MSCs were administered intravenously. No obvious adverse effects were noted. The treatment was repeated 3 and 6 days following the initial treatment. Two days after the infusion of her third dose, she was transferred out of the ICU with normal vital signs and laboratory values and a negative throat swab test for COVID-19 antigen. Although this study was limited to just one critically ill patient, the positive outcome supports further investigation.
Leng and colleagues reported similar improvements with intravenous administration of UC-MSCs into seven patients with COVID-19 noting improved functional outcomes and facilitation of recovery [9, 241]. The patients selected were positive for SARS-CoV-2, with one displaying critically severe type, four patients exhibited severe types, and two with milder symptoms of disease. An additional three patients with severe types were enrolled for placebo control. Prior to MSC infusion, all of the patients displayed high fever, shortness of breath, low oxygen saturation and pneumonia. When symptoms worsened, the patients received 1 x106 UC-MSCs/kg bw intravenously and were closely followed for 14 days. Virtually all symptoms subsided within 2-4 days subsequent to MSC infusions with no adverse effects. Chest CT imaging demonstrated that pneumonia infiltration significantly subsided. The majority of patients tested negative for the SARS-CoV-2 nucleic acid test at a week or two after MSC infusion. They found that MSC could significantly improve the functional outcomes of 7 patients without any observed adverse effects. Although no short-term adverse effects were observed, long-term follow up after MSC administration will be necessary in future clinical studies.
The mechanisms underlying the improvement after MSC infusion appears to be the result of robust anti-inflammatory activity. Such processes include an increased number of peripheral lymphocytes, the decline in the C-reactive protein, and decrease of over-activated cytokine-secreting immune cells (CXCR3+ CD4+ T cells, CXCR3+ CD8+ T cells, and CXCR3+ NK cells). Moreover, a group of CD14+ CD11c+ CD11bmid regulatory dendritic cell (DC) population increased after MSC treatment. In comparison to the placebo group, the MSC-infused patients demonstrated a decreased level of TNF-a, and concurrent elevation in the concentration of IL-10, suggesting an improved cytokine milieu. RNA-sequencing showed that infused MSCs were negative for ACE2 and TMPRSS2, which implied that MSCs were free from SARS-CoV-2 infection. Also, the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis suggested that MSCs were involved in antiviral pathways. The results of these clinical studies in severely ill COVID-19-infected patients show that in vivo administration of MSCs may be a safe and effective approach for treating who are in pulmonary distress, including elderly patients with severe ARDS."
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02380-2
Waiting till gap is filled :)
https://stocktalkforums.com/forums/topic/srne-diagnostic-improvements-play-a-key-role-in-the-abatement-of-the-pandemic/
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced earlier this month major progress in the development of COVISHIELD through the license of intellectual property developed by the scientific team at the Icahn School of Medicine at Mount Sinai ("Mount Sinai"). Sorrento and Mount Sinai have entered into an Exclusive License Agreement for a collection of antibodies having SARS-CoV-2 neutralizing properties that were developed by Mount Sinai. The license also contemplates Sorrento and Mount Sinai pursuing future collaborations in developing humanized monoclonal antibodies for therapeutic applications. Sorrento Chairman and CEO, Dr. Henry Ji, commented, "We are pleased with the excellent COVISHIELD antibody candidates identified thus far, and we at Sorrento are committed to rapidly developing the COVISHIELD cocktail against known and emerging COVID-19 variants of concern. Sorrento looks forward to future collaborations with the respected research capabilities of Mount Sinai centered on the development of innovative anti-viral and anti-cancer therapeutic candidates."
I’m back in around $18 :)
$PDSB
looking forward to tomorrow with presentations and panel discussion. Hold for the gold! Diamond hands...
I keep ny shares and wait. This will be a diamond later this year.
The 8-k tells us officially Timios generates a lot of revenue and they are profitable....good to know... me Likee
$IDEX Ideanomics agreed to acquire 100% of the outstanding capital stock of Timios
Strong buy. When more people see this $PDSB then we will run hard. We will soon see more analytics with higher price target.
Hold your shares...
PDS Biotechnology Corp (PDSB) PT Raised to $12 at Oppenheimer (Earlier)
March 19, 2021 10:20 AM
Oppenheimer analyst Leland Gershell raised the price target on PDS Biotechnology Corp (NASDAQ: PDSB) to $12.00 (from $7.00) while maintaining ...
Hold strong.. $PULM will run soon...
$PDSB , stickied this post :)
$PDSB have so much potential. This is a keeper for LT...
Thanks for updated DD. I will sticky your posts...
I´m waiting and I have time :) $IDEX
yea I shared it anyway , but not real DD agree
$PDSB
Forecast
https://www.macroaxis.com/forecast/PDSB
Check out amazing DD of YouTube channel: AH Wealth
Nice!!!
nice!! thanks for sharing..
Buy and hold!!! $PDSB
BHAT DD
1. Growing earnings - next report has been pre-announced, we are looking at a 70% year over year increase
2. New Distribution deals - signed several deals with hundreds of school systems
3. Competitive buyout - late last year they bought a competitor, increasing their market share
4. VERY low P/E of just 5.6, will be even lower after the amazing report drops later this month
5. No cash issues - they did an offering just last month
Overall a very undervalued, growing, and profitable company.